PMID- 25784113
OWN - NLM
STAT- MEDLINE
DCOM- 20150716
LR  - 20201216
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 15
DP  - 2015
TI  - Clinically significant association between the maximum standardized uptake value 
      on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction 
      of the biological characteristics of renal cell cancer.
PG  - 1097
LID - 10.1186/s12885-015-1097-0 [doi]
LID - 114
AB  - BACKGROUND: The relationship between the clinicopathological features and 
      molecular changes associated with standardized uptake value (SUV) determined by 
      Positron emission tomography (PET) with [18F] fluorodeoxyglucose (18F-FDG PET) in 
      human renal cell carcinoma (RCC) has not been elucidated. On the other hand, 
      overactivation of the phosphatidylinositol 3'kinase (PI3K), serine/threonine 
      kinase Akt, and mammalian target of rapamycin (mTOR) pathway has been detected in 
      a variety of human cancers, including RCC. So far, little is known about the 
      relationship between the SUV and these proteins in human RCC. Thus, it is 
      important to study the relevance of SUV with clinicopathological features in 
      human RCCs from a molecular point of view. METHODS: Seventy-seven consecutive 
      patients with RCC who underwent nephrectomy and pretreatment determination of the 
      maximum SUV (SUVmax) by 18F-FDG PET were analyzed. We investigated the 
      relationship between the SUVmax, phosphorylated-Akt (Ser-473) (pAkt(Ser-473)), 
      phosphorylated-Akt (Thr-308) (pAkt(Thr-308), and phosphorylated-S6 ribosomal 
      protein (Ser-235/236) (pS6) protein levels in the primary tumor and various 
      clinicopathological features. RESULTS: The average SUVmax of the primary tumor 
      was 6.9 (1.5 to 40.3). A higher SUVmax was correlated with higher expression of 
      pAkt(Ser-473), pAkt (Thr-308), and pS6 protein in the primary tumor. A higher 
      SUVmax and increased expression of pAkt (Ser-473), pAkt (Thr-308), and pS6 of the 
      primary tumor was associated with less tumor differentiation, a higher pT stage, 
      regional lymph node involvement, microscopic vascular invasion, and distant 
      metastasis, as well as with early relapse following radical nephrectomy in 
      patients who had localized or locally advanced RCC without distant metastasis 
      (cTanyNanyM0) and with shorter overall survival in all patients. CONCLUSIONS: A 
      higher SUVmax on 18F-FDG PET is associated with elevated tumor levels of pAkt and 
      pS6 protein and with aggressive behavior and metastatic potential of RCC, as well 
      as with early relapse following radical nephrectomy and shorter overall survival. 
      These findings suggest that SUVmax may be useful for predicting the biological 
      characteristics of RCC.
FAU - Mizuno, Tomoya
AU  - Mizuno T
AD  - Department of Urology, Dokkyo Medical University, 880 Kitakobayashi Mibu, 
      Tochigi, 321-0293, Japan, mizuno-t@dokkyomed.ac.jp.
FAU - Kamai, Takao
AU  - Kamai T
FAU - Abe, Hideyuki
AU  - Abe H
FAU - Sakamoto, Setsu
AU  - Sakamoto S
FAU - Kitajima, Kazuhiro
AU  - Kitajima K
FAU - Nishihara, Daisaku
AU  - Nishihara D
FAU - Yuki, Hideo
AU  - Yuki H
FAU - Kambara, Tsunehito
AU  - Kambara T
FAU - Betsunoh, Hironori
AU  - Betsunoh H
FAU - Yashi, Masahiro
AU  - Yashi M
FAU - Fukabori, Yoshitatsu
AU  - Fukabori Y
FAU - Kaji, Yasushi
AU  - Kaji Y
FAU - Yoshida, Ken-Ichiro
AU  - Yoshida K
LA  - eng
PT  - Journal Article
DEP - 20150310
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blotting, Western/methods
MH  - Carcinoma, Renal Cell/*diagnostic imaging/enzymology/pathology
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Immunohistochemistry
MH  - Kidney Neoplasms/*diagnostic imaging/enzymology/pathology
MH  - Male
MH  - Middle Aged
MH  - Phosphorylation
MH  - Positron-Emission Tomography/*methods
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - *Radiopharmaceuticals
MH  - Ribosomal Protein S6 Kinases/*metabolism
PMC - PMC4357069
EDAT- 2015/03/19 06:00
MHDA- 2015/07/17 06:00
PMCR- 2015/03/10
CRDT- 2015/03/19 06:00
PHST- 2014/10/29 00:00 [received]
PHST- 2015/02/20 00:00 [accepted]
PHST- 2015/03/19 06:00 [entrez]
PHST- 2015/03/19 06:00 [pubmed]
PHST- 2015/07/17 06:00 [medline]
PHST- 2015/03/10 00:00 [pmc-release]
AID - 1097 [pii]
AID - 10.1186/s12885-015-1097-0 [doi]
PST - ppublish
SO  - BMC Cancer. 2015;15:1097. doi: 10.1186/s12885-015-1097-0. Epub 2015 Mar 10.